Physicians' Academy for Cardiovascular Education
A secondary analysis of the EMPEROR-Preserved shows that empagliflozin reduces the primary outcome regardless of background mineralocorticoid receptor antagonists (MRA) therapy. Reduction of total HF hospitalization was more pronounced in MRA nonusers.
ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.
ACC 2022 A subanalysis of FIDELITY shows that the nonsteroidal MRA finerenone resulted in CV and kidney benefits in both primary and secondary prevention groups in a patient population with CKD and T2DM.
The Independent Data Monitoring Committee of the EMPA-KIDNEY trial has recommended to stop the trial early due to positive efficacy. The EMPA-KIDNEY trial evaluates the effect of empagliflozin in adults with CKD.
A pooled analysis of PARADIGM-HF and PARAGON-HF shows that treatment with sacubitril/valsartan results in a reduction of the primary composite renal endpoint and slows eGFR decline compared to RAS inhibition.
Watch the videos in this series by a faculty of heart failure experts from Groningen, The Netherlands, and learn what a cardiologist needs to know about potassium binding!
Kevin Damman outlines the problem of hyperkalemia with regard to RAASi use. Moreover, he discusses which patients are at risk of hyperkalemia and could benefit from potassium binders. With question to test your knowledge.
Treatment with the SGLT2 inhibitor dapagliflozin resulted in a reduction of new-onset T2DM in patients with CKD and HF, in a pooled analysis using data of the DAPA-CKD and DAPA-HF trials.
Three experts talk about findings from clinical trials with the non-steroidal MRA finerenone in patients with CKD and T2DM and how to implement these findings in daily clinical practice.
A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.
The use of race in equations to estimate GFR is a subject of discussion. This study developed new eGFR equations that do not include race and compared the performance of current and new eGFR equations.
The findings from the FIGARO-DKD trial and the FIDELITY analysis with finerenone in T2DM patients across a broad spectrum of kidney disease were presented at the ESC 2021. What is the impact of these results on clinical practice?
